Impact of Conditioning Intensity on Clinical Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Relapse After First Transplantation

IF 9.9 1区 医学 Q1 HEMATOLOGY
Kazuki Yoshimura, Hideki Nakasone, Masaharu Tamaki, Hiroki Hosoi, Kazuaki Kameda, Naoyuki Uchida, Noriko Doki, Takahiro Fukuda, Satoshi Yoshihara, Yasuo Mori, Hirohisa Nakamae, Masatsugu Tanaka, Yuta Katayama, Tetsuya Eto, Yuta Hasegawa, Shuichi Ota, Satoshi Takahashi, Makoto Yoshimitsu, Fumihiko Ishimaru, Junya Kanda, Yoshiko Atsuta, Kimikazu Yakushijin
{"title":"Impact of Conditioning Intensity on Clinical Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Relapse After First Transplantation","authors":"Kazuki Yoshimura,&nbsp;Hideki Nakasone,&nbsp;Masaharu Tamaki,&nbsp;Hiroki Hosoi,&nbsp;Kazuaki Kameda,&nbsp;Naoyuki Uchida,&nbsp;Noriko Doki,&nbsp;Takahiro Fukuda,&nbsp;Satoshi Yoshihara,&nbsp;Yasuo Mori,&nbsp;Hirohisa Nakamae,&nbsp;Masatsugu Tanaka,&nbsp;Yuta Katayama,&nbsp;Tetsuya Eto,&nbsp;Yuta Hasegawa,&nbsp;Shuichi Ota,&nbsp;Satoshi Takahashi,&nbsp;Makoto Yoshimitsu,&nbsp;Fumihiko Ishimaru,&nbsp;Junya Kanda,&nbsp;Yoshiko Atsuta,&nbsp;Kimikazu Yakushijin","doi":"10.1002/ajh.27709","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Although second allogeneic hematopoietic cell transplantation HCT (HCT2) is a potentially curative treatment for patients relapsing after their first HCT (HCT1), it is associated with higher non-relapse mortality (NRM) compared with HCT1. Furthermore, while reduced-intensity conditioning (RIC) in HCT2 might decrease NRM, there is no consensus on which patients may benefit from RIC. We retrospectively analyzed 2478 patients who underwent HCT2 for relapse of hematologic malignancies after HCT1. In a multivariate analysis, older recipient age, short duration between HCT1 and HCT2, RIC in HCT1, HCT-CI ≥ 2, and ECOG PS ≥ 2 were associated with an increased risk of NRM. RIC in HCT2 was associated with better NRM compared to myeloablative conditioning (MAC) (hazard ratio [HR] 0.83, 95% confidence interval [CI]: 0.72–0.97; <i>p</i> = 0.018), but was not significantly associated with overall survival (OS) (HR 0.91, 95% CI: 0.82–1.01; <i>p</i> = 0.075). We observed a significant interaction for NRM between extensive cGVHD in HCT1 and the conditioning intensity of HCT2 (interaction <i>p</i> &lt; 0.001), meaning that the benefit of RIC in HCT2 was seen in patients with extensive cGVHD in HCT1, but not in those without cGVHD. RIC in HCT2 was also associated with superior OS in patients with extensive cGVHD in HCT1 (HR 0.68, 95% CI: 0.49–0.93; <i>p</i> = 0.02), with significant interaction between the conditioning intensity and the prior history of extensive cGVHD (interaction <i>p</i> = 0.01). This study suggests that RIC in HCT2 reduces NRM for HCT2 and improves OS, especially in patients with a history of extensive cGVHD.</p>\n </div>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"100 7","pages":"1185-1195"},"PeriodicalIF":9.9000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Hematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ajh.27709","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Although second allogeneic hematopoietic cell transplantation HCT (HCT2) is a potentially curative treatment for patients relapsing after their first HCT (HCT1), it is associated with higher non-relapse mortality (NRM) compared with HCT1. Furthermore, while reduced-intensity conditioning (RIC) in HCT2 might decrease NRM, there is no consensus on which patients may benefit from RIC. We retrospectively analyzed 2478 patients who underwent HCT2 for relapse of hematologic malignancies after HCT1. In a multivariate analysis, older recipient age, short duration between HCT1 and HCT2, RIC in HCT1, HCT-CI ≥ 2, and ECOG PS ≥ 2 were associated with an increased risk of NRM. RIC in HCT2 was associated with better NRM compared to myeloablative conditioning (MAC) (hazard ratio [HR] 0.83, 95% confidence interval [CI]: 0.72–0.97; p = 0.018), but was not significantly associated with overall survival (OS) (HR 0.91, 95% CI: 0.82–1.01; p = 0.075). We observed a significant interaction for NRM between extensive cGVHD in HCT1 and the conditioning intensity of HCT2 (interaction p < 0.001), meaning that the benefit of RIC in HCT2 was seen in patients with extensive cGVHD in HCT1, but not in those without cGVHD. RIC in HCT2 was also associated with superior OS in patients with extensive cGVHD in HCT1 (HR 0.68, 95% CI: 0.49–0.93; p = 0.02), with significant interaction between the conditioning intensity and the prior history of extensive cGVHD (interaction p = 0.01). This study suggests that RIC in HCT2 reduces NRM for HCT2 and improves OS, especially in patients with a history of extensive cGVHD.

调节强度对第一次移植后复发的第二次异体造血细胞移植临床结果的影响。
虽然第二次异体造血细胞移植HCT (HCT2)对于第一次HCT (HCT1)后复发的患者是一种潜在的治疗方法,但与HCT1相比,它具有更高的非复发死亡率(NRM)。此外,虽然HCT2中的降低强度调节(RIC)可能会降低NRM,但对于哪些患者可能从RIC中受益尚无共识。我们回顾性分析了2478例接受HCT2治疗血液恶性肿瘤HCT1后复发的患者。在一项多因素分析中,年龄较大、HCT1和HCT2之间持续时间短、HCT1中的RIC、HCT-CI≥2和ECOG PS≥2与NRM风险增加相关。与清髓调节(MAC)相比,HCT2患者的RIC与更好的NRM相关(风险比[HR] 0.83, 95%可信区间[CI]: 0.72-0.97;p = 0.018),但与总生存期(OS)无显著相关(HR 0.91, 95% CI: 0.82-1.01;p = 0.075)。我们观察到HCT1中广泛的cGVHD与HCT2的调节强度之间存在显著的NRM相互作用(相互作用p < 0.001),这意味着RIC在HCT1中广泛的cGVHD患者中有益处,但在没有cGVHD的患者中没有。HCT2中的RIC也与HCT1中广泛cGVHD患者的良好OS相关(HR 0.68, 95% CI: 0.49-0.93;p = 0.02),条件调节强度与既往广发cGVHD病史之间存在显著交互作用(交互作用p = 0.01)。该研究表明,HCT2患者的RIC可降低HCT2患者的NRM并改善OS,特别是在有广泛cGVHD病史的患者中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
15.70
自引率
3.90%
发文量
363
审稿时长
3-6 weeks
期刊介绍: The American Journal of Hematology offers extensive coverage of experimental and clinical aspects of blood diseases in humans and animal models. The journal publishes original contributions in both non-malignant and malignant hematological diseases, encompassing clinical and basic studies in areas such as hemostasis, thrombosis, immunology, blood banking, and stem cell biology. Clinical translational reports highlighting innovative therapeutic approaches for the diagnosis and treatment of hematological diseases are actively encouraged.The American Journal of Hematology features regular original laboratory and clinical research articles, brief research reports, critical reviews, images in hematology, as well as letters and correspondence.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信